Document is current

Article History

Received: 3 January 2025

Accepted: 6 May 2025

First Online: 17 May 2025

Change Date: 22 January 2026

Change Type: Update

Change Details: The original online version of this Article was revised: The Acknowledgements section in the original version of this Article was incomplete. It now reads: “With gratitude and enthusiasm, the authors would like to acknowledge those who enabled the completion of this trial through the nonclinical development of BBI-001, including Paddy Shivanand and Willi Stahl for drug substance manufacturing and qualification, Colleen Johnson for the execution of the nonclinical toxicology program, Cara Casseday and Yuri Stasiv for management of clinical operations, Steve Smith for contributions to data analysis, and Michael Riley for leadership and company operations. We also gratefully acknowledge the provision of isotopic iron and advice for isotope quantitation from the laboratory of Diego Moretti at Fernfachhochschule Schweiz."

Declarations

:

: All methods were carried out in accordance with relevant guidelines and regulations of the Australian Therapeutic Goods Administration (TGA). All experimental protocols were approved by the Bellberry Human Research Ethics Committee in consultation with the TGA. Studies were conducted under informed consent for all subjects and/or their legal guardians.

: Authors CS, JDG, and CB hold ownership interests in Bond Biosciences, Inc. All the remaining authors declare no conflict of interest.